Stock 605507 GUOBANG PHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Guobang Pharma Ltd.

Equities

605507

CNE100004NS2

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-05-23 EDT 		5-day change 1st Jan Change
18.06 CNY +0.44% Intraday chart for Guobang Pharma Ltd. -3.37% +2.85%
04-15 Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
01-27 Guobang Pharma Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The group's high margin levels account for strong profits.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GUOBANG PHARMA LTD. Stock Guobang Pharma Ltd.
+2.85% 1.38B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 728B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 603B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 360B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+1.35% 279B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 244B
B+
NOVARTIS AG Stock Novartis AG
+8.09% 207B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 205B
A+
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 605507 Stock
  4. Ratings Guobang Pharma Ltd.